Nanobiotix’s (NBTX) “Buy” Rating Reaffirmed at HC Wainwright

Nanobiotix (NASDAQ:NBTX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Friday, Zacks.com reports.

Nanobiotix Stock Performance

Shares of NASDAQ:NBTX opened at $5.81 on Friday. The business has a 50 day moving average price of $6.26 and a 200 day moving average price of $6.54. Nanobiotix has a twelve month low of $1.75 and a twelve month high of $11.00.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently raised its stake in Nanobiotix stock. Baillie Gifford & Co. grew its position in Nanobiotix S.A. (NASDAQ:NBTX) by 48.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,869,030 shares of the company’s stock after acquiring an additional 932,835 shares during the quarter. Baillie Gifford & Co. owned 6.09% of Nanobiotix worth $20,887,000 as of its most recent SEC filing. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.